Guiheen Lawrence P. sold 10,000 shares of ADMA BIOLOGICS, INC. at $13.92 for −$139k on Nov 16, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$139,200Shares × reported price
Shares traded
10,000Common Stock
Price per share
$13.92Reported price. Read footnotes for ranges.
% of reported position traded
13.59%This security and ownership context
Holdings after
63,599Direct
Trade date
Nov 16, 2026Sell
Filed
Nov 16, 2026, 9:05 PM ET1-day reporting delay
Accession
0001140361-26-044293Code S · Transaction 402393
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 73,599 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 16, 2026Option exercise10,000$5.00$50,000Trade 402392
Nov 16, 2026Option exercise10,000$0.00$0Trade 402394
3 transaction rows in this filing. Joint filers share the same rows.

ADMA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADMA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −21%1w ago −5%1d ago +1.6%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is the price at which the shares were sold. F2: Includes, as of the transaction date, (i) 5,345 unvested restricted stock units ("RSUs") granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date and that will be settled into common stock upon vesting; and (ii) 58,254 shares of common stock owned by the Reporting Person. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F3: These shares are held in the Lawrence P Guiheen Revocable Trust DTD 9/20/19, over which the Reporting Person retains control. F4: These shares are held in the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE ("Guiheen Irrevocable Trust"), over which the Reporting Person retains control. The Reporting Person disclaims beneficial ownership of the securities held by the Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. F5: The option was granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019. F6: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one-year anniversary of the Reporting Person's ceasing to serve as a director of the Issuer. The Reporting Person is exercising this option due, in part, to its near-term expiration date.